Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8(1):306. https://doi.org/10.1038/s41392-023-01521-5.

Article  PubMed  PubMed Central  Google Scholar 

Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.

Article  PubMed  Google Scholar 

Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308–20. https://doi.org/10.3324/haematol.2022.280801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol. 2019;184(1):45–59. https://doi.org/10.1111/bjh.15614.

Article  PubMed  Google Scholar 

Ansell SM, editor. Hodgkin lymphoma: diagnosis and treatment. Mayo Clinic Proceedings. Elsevier; 2015.

Sharma M, Bakshi AK, Mittapelly N, Gautam S, Marwaha D, Rai N, et al. Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. J Control Release. 2022;346:43–70. https://doi.org/10.1016/j.jconrel.2022.04.007.

Article  CAS  PubMed  Google Scholar 

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity aintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903–7. https://doi.org/10.1038/nature06309.

Article  CAS  PubMed  Google Scholar 

von Locquenghien M, Rozalen C, Celia-Terrassa T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest. 2021. https://doi.org/10.1172/JCI143296.

Article  Google Scholar 

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, editors. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Seminars in cancer biology. Elsevier; 2015.

Google Scholar 

Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–27. https://doi.org/10.1038/nri1936.

Article  CAS  PubMed  Google Scholar 

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48. https://doi.org/10.1016/j.immuni.2004.07.017.

Article  CAS  PubMed  Google Scholar 

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012.

Article  CAS  PubMed  Google Scholar 

Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61–73. https://doi.org/10.1016/j.immuni.2013.07.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Couzin-Frankel J. Cancer immunotherapy. American Association for the Advancement of Science; 2013.

Google Scholar 

Couzin J. Select T cells, given space, shrink tumors. American Association for the Advancement of Science; 2002.

Book  Google Scholar 

Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015;15(4):201–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomez-Melero S, Hassouneh F, Vallejo-Bermudez IM, Aguera-Morales E, Solana R, Caballero-Villarraso J. Tandem CAR-T cell therapy: recent advances and current challenges. Front Immunol. 2025;16:1546172. https://doi.org/10.3389/fimmu.2025.1546172.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulemzin SV, Kuznetsova VV, Mamonkin M, Taranin AV, Gorchakov AA. CAR T-cell therapy: balance of efficacy and safety. Mol Biol (Mosk). 2017;51(2):274–87. https://doi.org/10.7868/S0026898417020148.

Article  CAS  PubMed  Google Scholar 

Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148-65 e20. https://doi.org/10.1016/j.cell.2023.06.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13: 925985. https://doi.org/10.3389/fimmu.2022.925985.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salles G, Barrett M, Foa R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–73. https://doi.org/10.1007/s12325-017-0612-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25. https://doi.org/10.1093/annonc/mdv304.

Article  PubMed  Google Scholar 

Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–88. https://doi.org/10.1016/S1470-2045(20)30225-4.

Article  CAS  PubMed  Google Scholar 

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66. https://doi.org/10.1056/NEJMoa1606038.

Article  CAS  PubMed  Google Scholar 

Sheykhhasan M, La’ah AS, Ahmadieh-Yazdi A, Tanzadehpanah H, Mahaki H, Manoochehri H, et al. Bispecific T-cell engagers (BiTEs) in immunotherapy. Critical developments in cancer immunotherapy. IGI Global; 2024. p. 205–34.

Google Scholar 

Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.

Article  CAS  PubMed  Google Scholar 

Riccardi F, Dal Bo M, Macor P, Toffoli G. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front Pharmacol. 2023;14:1274088. https://doi.org/10.3389/fphar.2023.1274088.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Chen D, Lu Y, Dong SC, Ma R, Tang WY, et al. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther. 2022;29(2):167–77. https://doi.org/10.1038/s41417-021-00295-8.

Article  CAS  PubMed  Google Scholar 

Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Ann Hematol. 2023;102(1):13–29. https://doi.org/10.1007/s00277-022-05054-9.

Article  CAS  PubMed  Google Scholar 

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–44. https://doi.org/10.1056/NEJMoa1708984.

Article